MedTrace Logo

Safety and Efficacy Study of High Dose Colistin

NCT02162966 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2015-04-01

No results posted yet for this study

Summary

Colistin is a rapidly acting bactericidal antimicrobial agent that possesses a post antibiotic effect against MDRO Gram-negative bacteria, such as as Pseudomonas aeruginosa, Acinetobacterbaumannii, and Klebsiella pneumonia.

Conditions

Interventions

DRUG

High Dose Colistin

High Dose Colistin

DRUG

Standard Dose Colistin

Standard Dose Colistin

Sponsors & Collaborators

  • King Saud Medical City

    lead OTHER_GOV

Principal Investigators

  • Ahmed F Mady, PhD · King Saud Medical City

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162966 on ClinicalTrials.gov